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Abstract
Background:  β-cells are extremely rich in zinc and zinc homeostasis is regulated by zinc
transporter proteins. β-cells are sensitive to cytokines, interleukin-1β (IL-1β) has been associated
with β-cell dysfunction and -death in both type 1 and type 2 diabetes. This study explores the
regulation of zinc transporters following cytokine exposure.
Methods: The effects of cytokines IL-1β, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-
α) on zinc transporter gene expression were measured in INS-1-cells and rat pancreatic islets.
Being the more sensitive transporter, we further explored ZnT8 (Slc30A8): the effect of ZnT8 over
expression on cytokine induced apoptosis was investigated as well as expression of the insulin gene
and two apoptosis associated genes, BAX and BCL2.
Results: Our results showed a dynamic response of genes responsible for β-cell zinc homeostasis
to cytokines: IL-1β down regulated a number of zinc-transporters, most strikingly ZnT8 in both
islets and INS-1 cells. The effect was even more pronounced when mixing the cytokines. TNF-α
had little effect on zinc transporter expression. IFN-γ down regulated a number of zinc
transporters. Insulin expression was down regulated by all cytokines. ZnT8 over expressing cells
were more sensitive to IL-1β induced apoptosis whereas no differences were observed with IFN-
γ, TNF-α, or a mixture of cytokines.
Conclusion: The zinc transporting system in β-cells is influenced by the exposure to cytokines.
Particularly ZnT8, which has been associated with the development of diabetes, seems to be
cytokine sensitive.
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Background
The zinc content of pancreatic β-cells is among the highest
in the body [1] and zinc plays an important structural role
in many proteins by binding protein molecules in dimers
and, in the case of insulin, in oligomers. Insulin is stored
as hexameric complexes chelating two zinc ions within
vesicles in a crystalline state [2]. Furthermore, zinc is an
important determinant of β-cell survival and a co-factor in
metalloenzymes and zinc-dependent transcription factors
[3,4]. Evidence that β-cell derived zinc is a major regulator
of glucagon secretion is emerging [5,6]. Finally, the activ-
ity of β-cell L-type calcium channels, involved in insulin
secretion, is partly regulated by zinc [7].
Diabetes affects zinc homeostasis [8] resulting in hypoz-
incaemia, hyperzincuria and, most likely, a generalized
zinc deficiency [2,9,10]. We have previously shown that
the zinc content of β-cells is glucose dependent [11].
Regulation of zinc homeostasis is ensured by zinc trans-
porters assigned to two metal transporter families: the ZIP
proteins (SLC39a) and the ZnT proteins (SLC30a). ZIPs
facilitate influx of zinc to the cytosol from the outside of
cells or from the lumen of intracellular compartments
while ZnTs ensure zinc efflux from cytosol to the outside
of cells or to intracellular organelles [12]. The mammalian
ZIP family comprises 14 proteins and the ZnT family 10
proteins, respectively [13]. The expression of a number of
zinc transporters depend on ambient glucose concentra-
tions [14,15]. Zinc levels are higher in ZnT8 over express-
ing cells with a higher zinc accumulation capacity and an
enhanced glucose mediated insulin secretion. Further-
more, over expression of this protein has been reported to
protect cultured β-cells from cell death induced by zinc
depletion [16]. In the brain, the lack of specific zinc trans-
porters, particularly ZnT3, is associated with apoptosis
and amyloid deposition [17]. Sladek et al. [18] identified
polymorphisms in the SLC30a8 gene encoding for the
zinc transporter ZnT8 as a major genetic risk factor for the
development of Type 2 diabetes, this was recently con-
firmed [19-21]. ZnT8 also appears to be a major humoral
autoantigen involved in the pathogenesis of type 1 diabe-
tes [22]. No genetic association between SLC30A8 and
type 1 diabetes has been found [23,24].
Cytokines are well known mediators of cell death in the
mature β-cell. This is due to the downstream signaling
events orchestrated by the main inflammatory cytokines,
TNF-α, IFN-γ, and IL1-β [25,26]. IL-1β alone or in combi-
nation with TNF-α and/or IFN-γ is toxic to β-cells in rat,
mouse, and human islets and is in part mediated by tran-
scriptional changes in the β-cells [27]. Destruction of β-
cells is induced by highly reactive agents both oxygen
derived free radicals and nitric oxide (NO) [8], which
increase apoptosis [28] and decrease insulin production
and release [29]. IL-1β is known to facilitate transcription
of inducible NO-synthase (iNOS) by the activation of
NFkB [30]. Data suggest that islets exposed to IL-1β have
an impaired first phase insulin secretion [31]. Stimulation
or over expression of different defense mechanisms pro-
tects β-cells against the toxic effect of cytokines [32-34].
Thus glucose responsive β-cells seem to be protected by
anti apoptotic proteins. It has been shown that exposure
to IL-1β and IFN-γ causes down regulation of the anti-
apoptotic protein Bcl2 before the onset of apoptosis [35].
On the other hand, it has been established that the Bax
protein promotes apoptosis in the β-cell [36].
Here we aim to explore whether cytokines influence zinc
transporter expression and to provide a profile of the alter-
ations. Having defined the more sensitive transporter,
ZnT8, we explore the effects of over expression on the out-
come of cytokine exposure to β-cells. We thus examine the
hypothesis that the toxic effects of cytokines include regu-
lation of zinc transporter genes.
Methods
Cell cultures
INS-1 and INS-1E cells were cultured in a 5% CO2 atmos-
phere in complete RPMI 1640 supplemented with 11 mM
glucose, 10% heat-inactivated fetal bovine serum, 50 μM
beta-mercaptoethanol, 2 mM L-Glutamine, 100 U/mL
penicillin, and 100 g/mL streptomycin. For stimulation
assays cells were plated (106 cells/well) into 6-well plates
(NUNC, Roskilde, Denmark). The INS-1 cells were treated
with 60–180 U recombinant mouse IL-1β/mL, 200 U
TNF-α/mL, 200 U recombinant Rat IFN-γ/mL or a mix-
ture, consisting of 180 U IL-1β/mL, 200 U TNF-α/mL and
200 U Rat IFN-γ/mL (PharMingen International, San
Diego, CA, USA). For INS-1 cells treatments were given for
1 and 24 hours, in replicas of 6. For INS-1E and INS-1E-
ZnT8-EGFP cells treatments were given for 6 and 24 hours
in replicas of 3. Controls were incubated with RPMI 1640
medium and 11 mM glucose. The stably transfected cell
line INS-1E-ZnT8-EGFP was maintained as described
above with the addition of 75 μM G418 to maintain a
pure culture of cells expressing the ZnT8-EGFP construct.
Expression of the fusion protein was controlled by fluo-
rescence microscopy and by Q-PCR using ZnT8-EGFP spe-
cific primers (figure 1) [16].
Rat islet preparation
Isolation and culturing of islets from 3–6 day old Wistar
Furth rats (Charles River, Sulzfeldt, Germany) were as
described [37]. The islets were precultured for 7 days in
complete medium (RPMI 1640 with 100 U/mL penicillin
and 100 μg/mL streptomycin and 11 mM glucose) supple-
mented with 10% newborn calf serum (Invitrogen/Gibco,
Denmark). Five hundred randomly picked islets were
used per 1 mL of complete medium supplemented withBMC Endocrine Disorders 2009, 9:7 http://www.biomedcentral.com/1472-6823/9/7
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0.5% human serum and 11 mM glucose. Islets were
placed in 12-well plates (NUNC, Roskilde, Denmark),
one plate for each time point. Cytokine treatments were
given for 1, 2, 4, 6 and 24 hours in replicates of 4. Treat-
ments were with 250 pg/mL IL-1β/mL, 10 ng/mL IFN-γ or
a mixture, consisting of 250 pg/mL IL-1β and 10 ng/mL
IFN-γ. Controls were incubated for 24 hours at identical
conditions without addition of cytokines. At the end of
the stimulation periods the islets were transferred to
Eppendorf tubes for RNA isolation.
Isolation of total RNA
For INS-1E cells total RNA was isolated using RNeasy Mini
Kit 8 (Qiagen) according to the manufacturer's instruc-
tions. For archive material (islets and INS-1 cells) total
RNA was isolated using TriZol. In brief, each sample was
dissolved in 1 mL Trizol® reagent (Invitrogen) on ice. Tri-
zol was removed by addition of chloroform followed by
isopropanol precipitation. The precipitates were washed
using 75% ethanol. The amount and purity of total RNA
was quantified using photospectrometry by measuring
the optical density at 260 and 280 nm and the integrity
was checked by agarose gel electrophoresis.
Real time polymerase chain reaction
TaqMan assay
cDNA synthesis of archive (islets and INS-1 cells) material
was performed using the RT-PCR TaqMan Kit N808-0234
(Perkin Elmer) according to the manufacturer's instruc-
tions. RefSeq IDs used for primer design and TaqMan IDs
are listed in table 1. For the PCR-assay, 200 ng total RNA
was used as starting material for the cDNA preparation in
a reaction volume of 7.7 μL. Semi-quantitative RT-PCR
was carried out in 20 μL reaction containing 2 μL TaqMan
RT Buffer, 4.4 μL 25 mM MgCl2, 4 μL dNTP (200 μM), 1
μL random hexamer (100 pmol/μL), 0.4 μL RNAse Inhib-
itor, 0.5 μL MultiScribe Reverse Transcriptase (50 U/μL),
0.2  μL RNase free water and 7.7 μL RNA. Following
reverse transcription cDNA solutions were incubated for 5
min at 95° to inactivate transcriptase and then stored at -
20°.
RT-PCR was carried out in a volume of 20 μL per well in a
384-Well Optical Reaction Plates (A300990x) containing
1.0 μL TaqMan Expression Assay, 5.0 μL RNase free water,
10.0 μL TaqMan Universal PCR MasterMix (2×) (without
AmpErase UNG) and 4.0 μL cDNA template. The plate
was run on the Applied Biosystems 7900 HT Fast Real
Time PCR System. The following protocol was used: 95°
in 10 min for AmpliTaq Gold Enzyme Activation and
finally the PCR including 40 cycles with 95° in 15 sec for
denaturation and 60° in 1 min for annealing. To compen-
sate for variation in cDNA concentrations and PCR effi-
ciency between tubes, an endogenous control (beta-Actin)
was included for each sample and used for normalisation.
SYBR Green assay
SYBR Green assay was used for experiments in INS-1E
cells. Reverse transcription was performed on 500 ng total
RNA for 1 h at 42°C by using a T7-oligo(dT)24 primer
and Superscript II reverse transcriptase (Life Technolo-
Transfection of INS-1E cells with human ZnT8: Left panel shows fluorescence (green) marked ZnT8 RNA-probe positivity in  transfected cells, contrasting the void control cells, middle panel Figure 1
Transfection of INS-1E cells with human ZnT8: Left panel shows fluorescence (green) marked ZnT8 RNA-
probe positivity in transfected cells, contrasting the void control cells, middle panel. Right panel shows the light 
microscopic appearance of the same cells.
Table 1: Primer sets used for real-time PCR; TaqMan assays 
were based on RefSeq ID.
Gene RefSeq ID TaqMan ID
ZnT3 NM_001013243.1 RN01472605_g1
ZnT4 NM_172066 RN01485635_m1
ZnT5 XM_226722.4 RN01493869_m1
ZnT6 XM_216643.4 RN01472402_m1
ZnT8 XM_001065623.1 RN01504406_m1
Zip5 XM_343140.3 RN01527166_g1
Zip6 NM_001024745 RN01405805_m1
beta-Actin NM_031144.2 RN01412977_g1BMC Endocrine Disorders 2009, 9:7 http://www.biomedcentral.com/1472-6823/9/7
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gies). Cycling was performed using an ICycler from Bio-
Rad as previously described. Whenever possible the
primers were placed in exons separated by an intron of at
least 500 bp. To avoid pseudogenes, at least one of the
primers was placed in a region distinct from these. To con-
firm that the primer pairs produced only unique products,
a dissociation protocol was performed after thermo-
cycling, thereby determining the dissociation of the PCR
products from 65°C to 95°C. The real-time PCR assay
included a no-template control and a standard curve of
five serial dilution points (in steps of 10-fold) of a pool of
the sampled cDNAs. All samples were amplified in dupli-
cate.
Quantification
Normalised Ct 's were calculated by subtracting the Ct-
mean of the normalisation genes for each sample and rel-
ative log2 fold changes were calculated using the compar-
ative delta-delta Ct method [38].
Cell death assays
MTT assay
Cells were plated in 96-well plates and allowed to attach
for 72 h. INS-1E and INS-1E-ZnT8-EGFP cells were then
treated with cytokines or control condition (no addition
of cytokines) for 6, 12, and 24 h. Each condition was per-
formed in replicates of six. The experiment was repeated
using cells grown from frozen stocks. The viability of each
experimental condition was determined using the MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] assay based on the activity of mitochondrial reduct-
ase enzymes. The assay was performed according to the
manufacturer's instructions (Roche). Briefly, following
experimental treatment, 10 μL of MTT solution was added
to the culture medium and the plate was incubated in the
dark for 3 hours at 37°C. A solubilisation buffer (100 μL)
was added and allowed to incubate overnight at 37°C.
Absorbance was measured at 570 nm using a ELX 808
microplate reader (Bio-Tek Instruments inc.). The per-
centage viability was calculated as follows: relative specific
viability = [(A-B)/(C-B)] ×100 where A = ABS570 of the
treated sample, B = ABS570 of the medium, and C =
ABS570 of the control. The values were expressed as via-
bility relative to control for each cell line.
Apoptosis/Necrosis assay
Cells were plated and treated as described in the MTT
assay section and cell death was measured using the Cell
Death Detection ELISA-plus assay (Roche) according to
the manufacturer's instructions. Following experimental
treatment culture supernatants were isolated and the cells
were harvested in lysis buffer. After centrifugation culture
supernatants and cell lysates were used to determine the
amount of necrosis and apoptosis, respectively, in a quan-
titative sandwich-enzyme-immunoassay. Absorbance was
measured at 405 nm and the viability was calculated as
described in the MTT section. The assay was repeated twice
as described above.
Statistical analyses
Date are presented as means +/- s.e.m.. Anova analyses
were performed to include a plate effect in INS-1 cells. Sta-
tistical significance of differences between stimulation
and control was found using Student's t-tests. Anova anal-
yses were performed on islet data. For the cell death assays
results were considered significant at p < 0.01 in repeated
experiments.
Results
Significant differences between cytokine treated and con-
trol INS-1 cells are listed in table 2. Cytokines mostly
down regulated zinc transporter expression. The down
regulation in most cases increased over time. TNF-α treat-
ment had almost no effect, whereas IL-1β, IFN-γ, and a
mixture of cytokines all gave rise to down regulations of
some of the genes. ZnT6 and ZnT8 were down regulated
at both 1 and 24 hours, whereas ZnT3 was down regulated
at 24 hours only. ZnT5 and Zip5 expression seemed not to
be affected by cytokines and ZnT4 was only weakly influ-
enced. Finally, Zip6 was influenced by IL-1β stimulation
only, and at 24 hours only. A mixture of cytokines gener-
ally increased the down regulation.
Table 2: Regulation of ZnT/Zip expression in INS-1 cells following cytokine exposure. 
IL-1β/6 h IL-1β/24 h TNF-α/6 h TNF-α/24 h IFN-γ/6 h IFN-γ/24 h Mix./6 h Mix./24 h SEM
ZnT3 0.00 -0.58** -0.14 0.00 -0.14 -0.93** -0.14 -1.85** +/- 0.20
ZnT4 -0.38 0.00 -0.14 0.49* -0.49* -0.38* -0.49* 0.26 +/- 0.19
ZnT5 -0.14 0.00 0.00 0.26 -0.38 -0.38 -0.38 -0.26 +/- 0.23
ZnT6 -0.26** -0.26** -0.14 0.00 -0.26** -0.26* -0.14* -0.14 +/- 0.09
ZnT8 -0.38* 0.26 -0.14 0.26 -0.49** -0.38** -0.49** -1.81** +/- 0.16
Zip5 0.00 -0.14 -0.14 0.38 0.14 -0.77* -0.26 -0.38 +/- 0.36
Zip6 -0.00 -0.85** 0.00 0.00 -0.26 0.38* -0.14 -1.00** +/- 0.15
Log2-fold changes are indicated (n = 6). (* p < 0.05, ** p < 0.01). Mix. is IL-1β+TNF-α+IFN-γ IL-1β. The last column indicates standard errors +/- 
SEM for log2 fold changes.BMC Endocrine Disorders 2009, 9:7 http://www.biomedcentral.com/1472-6823/9/7
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In islets there was no change over time for IFN-γ stimula-
tion, whereas ZnT6 and ZnT8 showed significant changes
over time for both IL-1β and the stimulation with IL-1β+
IFN-γ (table 3). There were significant differences between
the three treatments at 24 hours for ZnT5, ZnT6 and ZnT8
(table 4). Figure 2 shows the time course for the difference
between the IL-1β stimulation and the IFN-γ stimulation
for ZnT5, ZnT6, ZnT8, Zip5 and Zip6. For these genes
there was a systematic development over time. As in INS-
1 cells a mixture of cytokines generally increased the down
regulation. Cytokine stimulation for 24 hours resulted in
an overall down regulation of the insulin gene in islets
and INS-1 cells (results not shown). As for INS-1 cells,
ZnT8 was the most regulated zinc transporter in islets
where it was down regulated approximately 12 fold (~3.5
on a log2 scale).
The sensitivity to cytokines in INS-1E and INS-1E-ZnT8-
EGFP cells was estimated by measuring mitochondrial
activity (figure 3). No differences between the cell lines
were found after exposure to TNF-α. Compared to INS-1E,
IFN-γ decreased survival after 6 hours (but not after 12 or
24 hours). IL-1β decreased survival after 12 and 24 hours.
Cytokine mixtures decreased survival after 6 hours (but
not after 12 or 24 hours). These results were verified by an
independent assay specifically measuring apoptosis and
necrosis at 12, 24, and 36 hours with IL-1β and cytokine
mixture. Apoptosis was increased by 4 and 2 fold in the
ZnT8 transfected cell line following treatment with IL-1β
for 24 and 36 hours, respectively (table 5). No differences
were observed between the cell lines using the cytokine
mixture. In addition, BCL2 and BAX mRNA expressions
were compared between the cell lines at 6 and 24 hours
(figure 4). Two of the housekeeping genes (beta-Actin and
Cyclophilin A) showed a marked difference between the
two cell lines and the two time points. Expression of the
housekeeping gene UBC7 showed no difference between
the two cell lines and a minor difference between the two
time points. None of the housekeeping genes showed a
difference between the treatments. UBC7 was therefore
used as the normalizing gene. BAX and BCL2 showed no
response to cytokine treatment (p = 0.07 and p = 0.13),
but both genes showed a strong time effect (p < 0.0001
and p = 0.0001), and BAX exhibited a higher expression in
the INS-1E-ZnT8-EGFP cells (p < 0.0001). Insulin gene
expression showed a difference between the two cell lines
and a difference between the two time points. On top of
that IL-1β decreased the expression of insulin in INS-1E-
ZnT8-EGFP cells (p = 0.0001) and a mixture of cytokines
decreased the expression for both cell lines (p < 0.0001).
Discussion
The present study demonstrates that cytokines regulate
the expression of zinc transporter mRNA in β-cells. This
may relate to both loss of cell mass (as is the case in the
central nervous system [17]) and to decreased secretory
capacity [16]. Evidence that zinc homeostasis is important
for the development of diabetes is emerging from a
number of association studies [18-20,22]. Zinc is concen-
trated in islet cells and related to insulin synthesis, storage
and secretion [39]. Hypozincemia is a common feature in
diabetes [40,41] and zinc supplementation has been
shown to inhibit the development of experimental type 1
diabetes in mice [42]. Moreover, zinc can improve hyper-
glycemia in streptozotocin-diabetic mice [34]. We have
previously described that some, but not all, ZnTs and ZIPs
are influenced by ambient glucose levels and zinc concen-
trations in β-cells, suggesting an active role for these pro-
teins. ZnT3 and ZnT8 appear to be of particular interest
[14,15].
In the present study, cytokines generally down regulated
the expression of zinc transporters in both islets and INS-
1 cells and we found an increased regulation over time. In
most cases, zinc transporter expression was similar for
INS-1 cells and islets but of greater magnitude in islets.
Some of the discrepancies may be due to the presence of
other cell types in islets. Also, TNF-α was not tested in
islets limiting the conclusions for this cytokine. Compar-
ing individual cytokines showed that some zinc transport-
ers, namely ZnT5, ZnT6 and ZnT8, exhibited similar
expression profiles indicating that these transporters may
Table 3: Regulation of ZnT/Zip expression in islets following 
cytokine exposure (n = 4).
IL-1β IFN-γ IL-1β+ IFN-γ
ZnT3 0.7* 30.5 38.9
ZnT4 86.3 62.9 17.9
ZnT5 7.0 67.7 0.1*
ZnT6 1.40* 31.7 1.4*
ZnT8 0.0* 50.9 0.0*
Zip5 14.6 88.1 52.8
Zip6 27.0 55.4 41.5
P-values in percent for the hypothesis of no change over time are 
given. (*) p-values below 5% are highlighted.
Table 4: Regulation of ZnT/Zip expression in islets following 
cytokine exposure (n = 4). 
1  h2  h4  h6  h2 4  h
ZnT3 87.7 51.3 11.5 1.6* 25.2
ZnT4 40.8 69.8 54.0 36.9 25.8
ZnT5 62.5 99.3 50.9 22.4 1.1*
ZnT6 86.9 80.6 77.3 18.0 1.1*
ZnT8 76.5 75.7 46.3 0.8* 0.0*
Zip5 82.7 84.7 74.2 62.4 10.9
Zip6 55.6 90.8 80.3 26.5 5.0
P-values in percent for the hypothesis of no difference between 
treatments are given. (*) p-values below 5% are highlighted.BMC Endocrine Disorders 2009, 9:7 http://www.biomedcentral.com/1472-6823/9/7
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share regulatory transcriptional mechanisms [43]. The
mixture of cytokines, mimicking the in vivo cytokine load
in islet inflammation, augmented the responses seen with
the individual cytokines. Notably ZnT8 responded with
very large significant down regulations to both IL-1β and
the cytokine mixture. Excessive apoptosis of pancreatic β-
cells has been associated with diabetes [44]. It has been
shown that zinc depletion by itself can induce apoptosis
[45] and it may also promote apoptosis induced by oxida-
tive stress [46], thereby participating in reduction of β-cell
Zinc transporter expression profiles for ZnT5, ZnT6, ZnT8, Zip5, and Zip6 following cytokine exposure in islets Figure 2
Zinc transporter expression profiles for ZnT5, ZnT6, ZnT8, Zip5, and Zip6 following cytokine exposure in 
islets. The figure shows the time course for the log2 difference +/- SEM between the IL-1β stimulation and the IFN-γ stimula-
tion, showing a systematic development over time for the indicated genes. (n = 4). Black; ZnT5, red; ZnT6, green; ZnT8, blue; 
Zip5, purple; Zip6.BMC Endocrine Disorders 2009, 9:7 http://www.biomedcentral.com/1472-6823/9/7
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mass. Enhanced capacity of the β-cell to store zinc may
therefore protect against zinc depletion and oxidative
stress [16]. On the other hand, some of the changes in
intracellular zinc concentrations that can be expected
from the changes in transporter expression described here
might increase the intracellular load of free zinc ions and
may add yet another mechanism for cell death since it has
previously been demonstrated that an exaggerated trans-
membrane zinc transport can severely affect beta-cell sur-
vival by a direct toxic effect of zinc [47].
Evidence suggests that ZnT8 enhances zinc storage in
insulin granules and is directly implicated in the insulin
secretion pathway. In this study we found that INS-1E
cells over expressing ZnT8 were more sensitive to IL-1β
induced apoptosis. Interestingly, compared to wild type
cells, the cytokines IFN-γ and TNF-α as well as the
cytokine mixture did not result in increased apoptosis,
suggesting that ZnT8 may be affected by signalling path-
ways regulated by IL-1β. Palmer et al. [48] showed that
sensitivity towards IL-1β depends on the metabolic status
Table 5: Induction of apoptosis/necrosis in INS-1E-ZnT8-EGFP cells relative to INS-1E cells following cytokine exposure (n = 3). 
IL-1β/12 h IL-1β/24 h IL-1β/36 h Mix/12 h Mix/24 h Mix/36 h
Apoptosis - *4.1 +/- 0.21 *1.8 +/- 0.23 - - -
Necrosis - - - - - -
Data represent mean of two independent experiments. Fold changes between cell lines are indicated. (*) p < 0.05 in both experiments. Only 
significant changes are shown +/- SEM. Mix. is IL-1β+TNF-α+IFN-γ IL-1β.
Relative survival for INS-1E and INS-1E-ZnT8-EGFP cells following cytokine exposure after 6, 12, and 24 hours was estimat- edby MTT Figure 3
Relative survival for INS-1E and INS-1E-ZnT8-EGFP cells following cytokine exposure after 6, 12, and 24 hours 
was estimatedby MTT. Values were calculated relative to control cells for each cell line +/- SEM (n = 6). (*) p < 0.01 indi-
cates significance in two independent experiments.
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of the β-cell indicating that over expression of ZnT8 may
increase the metabolic activity. Hence, contrasting previ-
ous studies, over expression of ZnT8 was not protective
with respect to cytokine exposure. However, siRNA knock-
down of this gene seems to increase the sensitivity of INS-
1E cells (unpublished observation) suggesting that the
level of protein and specific stressor are important for the
outcome. Cytokines mediate β-cell death by varying path-
ways and are instrumental in the reduction of β-cell mass
in both type 1 and type 2 diabetes [49]. β-cell destruction
is the result of islet infiltration and an inflammatory
response elicited by secretion of pro-inflammatory
Log2 expression levels relative to UBC7 for beta-Actin, Cyclophilin A, BAX, BCL2, and insulin in INS-1E and INS-1E-ZnT8- EGFP cells (n = 3) Figure 4
Log2 expression levels relative to UBC7 for beta-Actin, Cyclophilin A, BAX, BCL2, and insulin in INS-1E and 
INS-1E-ZnT8-EGFP cells (n = 3). The last plot indicates the expression level of the normalizing gene UBC7. Black; INS-1E 
cells, red; INS-1E-ZnT8-EGFP cells. Circles; 6 hour treatments, triangles; 24 hour treatments.BMC Endocrine Disorders 2009, 9:7 http://www.biomedcentral.com/1472-6823/9/7
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cytokines and chemotactic factors leading to insulinope-
nia and hyperglycemia [50]. Both IL-1β and TNF-α con-
tribute to pancreatic β-cell death in type 1 diabetes
probably via activation of transcription factor nuclear fac-
tor-kappa-B (NF-kappaB). IL-1β is associated with a more
severe induction of cell death compared to TNF-α and was
also observed in the present study (data not shown).
Recent studies suggest that these differences may partly be
explained by a stronger induction of NF-kappaB and its
target genes by IL-1β [51]. The ZnT8 over expressing cell
line exhibited a higher basal level of apoptosis compared
to control cells indicating an increased pro-apoptotic
environment per se. In line with this, the relative expres-
sion of BAX (pro-apoptotic) was higher in the transfected
cell line and no difference was found for BCL2 (anti-apop-
totic). Expressions of the insulin gene were significantly
down regulated by similar magnitudes in both cell lines
corroborating previous observations [29].
Conclusion
In summary, the present study demonstrates for the first
time that regulation of zinc transporters is sensitive to pro-
inflammatory cytokines.
These data suggest that cytokines might contribute to the
disturbed intracellular zinc homeostasis seen in β-cells of
type 1 and type 2 diabetic patients. Furthermore, over
expression of ZnT8 may sensitize INS-1E cells to apopto-
sis via IL-1β indicating a possible role for this protein in β-
cell apoptosis. However, further mechanistic studies
should be performed to determine the specific role for
ZnT8 in the downstream events from IL-1β causing β-cell
apoptosis.
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